International Scholarly Research Notices / 2013 / Article / Tab 3

Research Article

Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients

Table 3

Safety comparison on hepatic, renal, and muscular functions: adverse events after 2 years of statin use.

VariablesAtor 
10 mg 
(%)
Ator 
20 mg 
(%)
Ator 
40 mg 
(%)
Ros 
10 mg 
(%)
Ros 
20 mg 
(%)
Prav 
20 mg 
(%)
Prav 
40 mg 
(%)

Hepatic function
 ALT > 3 × ULN0000000
Renal function
 Normal
  (eGFR ≥ 90 mL/min/1.73 m2)
38 (76.0)32 (64.0)30 (60.0)37 (74.0)30 (60.0)34 (68.0)30 (60.0)
 Mild
 (eGFR 60–89 mL/min/1.73 m2)
10 (20.0)14 (28.0)16 (32.0)9 (18.0)14 (28.0)11 (22.0)15 (30.0)
 Moderate
 (eGFR 30–59 mL/min/1.73 m2)
2 (4.0)4 (8.0)5 (10.0)4 (8.0)6 (12.0)5 (10.0)4 (8.0)
 Severe
 (eGFR 15–29 mL/min/1.73 m2)
0000000
 Kidney failure
 (eGFR < 15 mL/min/1.73 m2)
0000000
Microalbuminuria
 At baseline without ACE inhibitors
 and/or ARBs
2 (4.0)2 (4.0)01 (2.0)1 (2.0)2 (4.0)4 (8.0)
 At 2 years after without ACE inhibitors
 and/or ARBs
2 (4.0)2 (4.0)01 (2.0)1 (2.0)1 (2.0)1 (2.0)
 At baseline with ACE inhibitors
 and/or ARBs
8 (16.0)17 (34.0)11 (22.0)15 (30.0)13 (26.0)12 (24.0)17 (34.0)
 At 2 years after with ACE inhibitors 
 and/or ARBs
8 (16.0)20 (40.0)14 (28.0)17 (34.0)14 (28.0)15 (30.0)18 (36.0)
Macroalbuminuria0000000
CK level
 >10 × ULN0000000